Fluvoxamine

Fluvoxamine

SCHEMBL35225

COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A4

The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 10/20 0.83
MEN1 O00255 2/20 1.00
LMNA P02545 2/20 1.00
KMT2A Q03164 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
ATM Q13315 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
CYP1A2 P05177 2/20 0.83
CYP3A4 P08684 2/20 0.83
CYP2D6 P10635 2/20 0.83
CYP2C9 P11712 2/20 0.83
CYP2C19 P33261 2/20 0.83
HIF1A Q16665 2/20 0.83
NFKB1 P19838 1/20 0.83
SLC6A2 P23975 1/20 0.83
ADRA1A P35348 1/20 0.83
OPRK1 P41145 1/20 0.83
SLC6A3 Q01959 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluvoxamine SCHEMBL7339196 1.00 MEN1 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL29014388 1.00 MEN1 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL3863487 1.00 MEN1 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL31022880 1.00 MEN1 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL782847 1.00 MEN1 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL31495839 0.93 MEN1 (0.87) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL27816994 0.91 SLC6A4 (0.95) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL5569574 0.91 SLC6A4 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL341698 0.91 SLC6A4 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM
Fluvoxamine SCHEMBL178609 0.91 SLC6A4 (1.00) MEN1LMNAKMT2ASMN1; SMN2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4252 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624037-B2 Method of treating agitation, aggressive behavior, and impulse control disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12624036-B2 Method of treating post-traumatic stress disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
EP-4566590-A1 TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF Harbin Kanon Pharmaceutical Co., Ltd (CN) 2025-06-11 EP claimed
CN-119595798-A High performance liquid chromatography for efficiently separating and detecting isomer impurities in fluvoxamine maleate 河北医科大学 2025-03-11 CN claimed
CN-115998697-B Preparation method of fluvoxamine maleate film coated tablet 河北龙海药业有限公司 2025-01-28 CN claimed
US-20240295545-A1 GLIOMA THERAPY IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2024-09-05 US claimed
CN-117462516-B Sustained-release pellet, preparation method thereof and pellet tablet thereof 青岛海洋生物医药研究院 2024-08-30 CN claimed
CN-117503707-B Taste-masking microsphere and preparation process and application thereof 哈尔滨市康隆药业有限责任公司 2024-08-23 CN claimed
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
CN-118121555-A Fluvoxamine maleate tablet and preparation method thereof 重庆赛维药业有限公司 2024-06-04 CN claimed
EP-1273301-A2 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON S.A. (CH) 2003-01-08 EP claimed
WO-2002085297-A2 COMPOSITIONS & FORMULATIONS WITH A NON-GLUCOCORTICOID STEROID &/OR A UBIQUINONE & KIT FOR TREATMENT OF RESPIRATORY & LUNG DISEASE EAST CAROLINA UNIVERSITY (US) 2002-10-31 WO claimed
US-6433225-B1 REACTING A OXIME WITH 2-CHLOROETHYLAMINE HYDROCHLORIDE SUN PHARAMACEUTICAL INDUSTRIES, LTD. (IN) 2002-08-13 US claimed
US-6395788-B1 FATIGUE, CHRONIC FATIGUE SYNDROME, PAIN, AND AUTOIMMUNE DISEASE TREATMENT; SIDE EFFECT REDUCTION VELA PHARMACEUTICALS, INC. 2002-05-28 US claimed
EP-1202721-A1 CYCLOBENZAPRINE FOR TREATING GENERALIZED ANXIETY DISORDER AND COMPOSITIONS THEREOF Vela Pharmaceuticals Inc. (US) 2002-05-08 EP claimed
US-6358944-B1 ADMINISTERING CYCLOBENZAPRINE OR METABOLITE; SIDE EFFECT REDUCTION VELA PHARMACEUTICALS, INC. 2002-03-19 US claimed
US-20010046988-A1 Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine VELA PHARMACEUTICALS, INC. 2001-11-29 US claimed
WO-2001012174-A1 CYCLOBENZAPRINE FOR TREATING GENERALIZED ANXIETY DISORDER AND COMPOSITIONS THEREOF VELA PHARMACEUTICALS INC. (US) 2001-02-22 WO claimed
US-5795895-A Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug ANCHORS J MICHAEL (US) 1998-08-18 US claimed
WO-1992018005-A1 METHOD OF TREATING TRICHOTILLOMANIA AND ONYCHOPHAGIA NATIONAL INSTITUTES OF HEALTH (US) 1992-10-29 WO claimed